Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Claude Abujrab-saba (NPI 1982754040)

Field	Value
Entity Type	Individual
Organization	Claude Abujrab-saba
Address	1860 Town Center Dr
City	Reston
State	VA
ZIP	20190
Taxonomy	Rheumatology Physician
NPI Enumerated	January 11, 2007

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

Provider profile and scale: CLAUDE ABUJRAB-SABA is listed as a Rheumatology Physician with an NPI enumerated on 2007-01-11 (~19 years ago) and has $2.9M in total Medicare revenue on file, with no Medicaid billing recorded. This is effectively a Medicare-centric practice in scale and tenure.

Revenue concentration: the precomputed top-3 finding shows that the top 3 Medicare codes by revenue account for 68.3% of this provider's total Medicare revenue. Those three codes are J0717 ($942.4K, 31.7% of Medicare revenue), J0129 ($629.9K, 21.2% of Medicare revenue), and J0897 ($460.1K, 15.5% of Medicare revenue), indicating heavy concentration in a small set of product/administration lines.

Service-line implications: the code mix is dominated by high-cost biologic and injectable therapy administration rather than routine evaluation-and-management visits, with leading drug codes J0717, J0129, and J0897 and additional administered products such as J1745, J3111, and J3262. The presence of chemotherapy/infusion administration codes (96401, 96413, 96415, 96365) and multiple injected biologics suggests the practice operates an in-office drug administration service (subcutaneous/IM and IV), consistent with a clinic that delivers and bills biologic therapies on site.

Payer mix and exposure: Medicare is the sole payer present in the records ($2.9M Medicare revenue and none for Medicaid), so the provider has essentially single-payer exposure to Medicare and minimal to no Medicaid-facing volume. For payers and networks that manage dual-eligibles or Medicaid populations, this provider would not represent meaningful Medicaid capacity based on these files.

Competitive standing on top biologics: this provider ranks very highly for certain biologics nationally — J0717 ranks #19 of 848 providers (98th percentile, described as notably above typical national volume) and J0897 ranks #149 of 10057 providers (99th percentile, described as an extreme outlier). By contrast, J0129 ranks #159 of 1221 providers (87th percentile, described as typical), which together indicate the provider is a major national-volume administrator for specific drugs rather than uniformly high volume across all biologic classes.

E/M vs drug revenue mix: evaluation and management codes are a minority of reported Medicare revenue compared with drug administration revenue; for example, 99214 generated $244.1K (8.2% of Medicare revenue) while individual drug codes such as J0717 produced $942.4K (31.7%). This pattern points to a business model where buy-and-bill drug administration and infusion services drive receipts more than face-to-face visit billing.

Notable administration outliers: beyond the drug codes, the practice shows outlier-level activity in chemotherapy/administration reporting — 96401 generated $114.9K and ranks #9 of 3868 providers (100th percentile, labeled an extreme outlier). Such ranking underscores unusually high in-office administration of nonhormonal, antineoplastic or related injectable therapies relative to national peers.

Implications for payer contracting and utilization management: the high concentration in a few billed biologics and extreme national ranks for specific codes suggests opportunities for targeted contract strategies (site-of-care policies, buy-and-bill pricing, or drug-specific pathway management) focused on J0717 and J0897. Given the lack of Medicaid billing, these opportunities and any utilization-management approaches would be relevant primarily to Medicare reimbursement and network arrangements rather than state Medicaid programs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	235,600	$1	$942.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	18,530	$30	$629.9K
J0897	Injection, denosumab, 1 mg	25,560	$20	$460.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,420	$100	$244.1K
J3111	Injection, romosozumab-aqqg, 1 mg	20,160	$10	$161.3K
J3262	Injection, tocilizumab, 1 mg	29,290	$10	$146.4K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,800	$60	$114.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,850	$30	$100.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$110	$49.1K
J3304	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	2,560	$10	$33.3K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Claude Abujrab-saba — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	5	30	10,450	$30	$407.3K
J3262	16	20	75,870	$1	$383.3K
J0717	3	30	74,500	$1	$361.7K
J1745	19	30	4,540	$30	$200.2K
J3111	11	20	19,740	$10	$190.2K
J0897	6	340	2,820	$20	$89.3K
96413	46	230	250	$100	$28.5K
J3304	5	20	1,380	$10	$28.3K
99214	17	12,890	140	$80	$21K
96401	2	180	110	$60	$11.5K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Claude Abujrab-saba, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Phong Nguyen	VA	Rheumatology Physician	$4.2M	$0
Alexia Gospodinoff	VA	Rheumatology Physician	$812.5K	$0
Brandon Miller	VA	Rheumatology Physician	$409.8K	$0
Carlton Miller	VA	Rheumatology Physician	$371.9K	$2.2K
Cynthia Morgan	DC	Rheumatology Physician	$50.5K	$53.6K

Nearby Providers

Other providers in the same ZIP code as Claude Abujrab-saba, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Reston Hospital Center LLC	VA	General Acute Care Hospital	$0	$14.9M
Reston Surgery Center, LP	VA	Ambulatory Surgical Clinic/Center	$2.8M	$869.2K
Dhruv Pateder	VA	Orthopaedic Surgery of the Spine Physician	$607.7K	$0
Ahmad Noori	VA	Nephrology Physician	$341.1K	$190.1K
Mark Tekrony	VA	Neurology Physician	$349.6K	$0
Theodore Sebastien	VA	MOHS-Micrographic Surgery Physician	$335.3K	$0
Andrew Siegel	VA	Ophthalmology Physician	$333.2K	$0
James Reeves	VA	Orthopaedic Surgery Physician	$307.6K	$0
Charles Seal	VA	Orthopaedic Surgery Physician	$301.5K	$0
Lavanya Nutankalva	VA	Infectious Disease Physician	$298.8K	$0

Claude Abujrab-saba — Billing Profile & Reimbursement Data

Sign up for Claude Abujrab-saba — Billing Profile & Reimbursement Data policy alerts

Claude Abujrab-saba — Billing Profile & Reimbursement Data

Sign up for Claude Abujrab-saba — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References